These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3202277)

  • 21. Anti-idiotype antibodies could explain inhibition of allergen-IgE binding to B cells after grass pollen immunotherapy.
    Simon MR
    J Allergy Clin Immunol; 2004 Jun; 113(6):1225; author reply 1225-6. PubMed ID: 15214366
    [No Abstract]   [Full Text] [Related]  

  • 22. Possible induction of oral allergy syndrome during specific immunotherapy in patients sensitive to tree pollen.
    Lee YD
    Med Sci Monit; 2005 Oct; 11(10):LE14. PubMed ID: 16192906
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety of sublingual grass pollen immunotherapy after anaphylaxis.
    Nichani JR; de Carpentier J
    J Laryngol Otol; 2009 Jun; 123(6):683-4. PubMed ID: 18501039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular diagnosis and immunotherapy.
    Sastre J; Sastre-Ibañez M
    Curr Opin Allergy Clin Immunol; 2016 Dec; 16(6):565-570. PubMed ID: 27685663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring of different forms of immunotherapy by measuring of grass pollen specific "blocking antibodies".
    Maasch HJ; Puttonen E
    Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M; 1983; (78):91-100. PubMed ID: 6625591
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunologic effects of encapsulated short ragweed extract: a potent new agent for oral immunotherapy.
    Litwin A; Flanagan M; Entis G; Gottschlich G; Esch R; Gartside P; Michael JG
    Ann Allergy Asthma Immunol; 1996 Aug; 77(2):132-8. PubMed ID: 8760779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [How and when is immunotherapy for pollen allergy carried out?].
    Kersten W
    Med Klin; 1980 Oct; 75(21):751-4. PubMed ID: 7453622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One grass or many? Does allergy distinguish among species?
    Kleine-Tebbe J
    Drugs Today (Barc); 2008 Dec; 44 Suppl B():65-7. PubMed ID: 19221623
    [No Abstract]   [Full Text] [Related]  

  • 29. Shooting for a faster approach to the immunotherapy target: will cluster become conventional?
    Cox LS
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):177-8. PubMed ID: 19354062
    [No Abstract]   [Full Text] [Related]  

  • 30. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
    Klimek L; Schendzielorz P; Pinol R; Pfaar O
    Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives.
    Purohit A; Niederberger V; Kronqvist M; Horak F; Grönneberg R; Suck R; Weber B; Fiebig H; van Hage M; Pauli G; Valenta R; Cromwell O
    Clin Exp Allergy; 2008 Sep; 38(9):1514-25. PubMed ID: 18564326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy (desensitization) in allergic disease.
    Norman PS
    Annu Rev Med; 1975; 26():337-44. PubMed ID: 1096771
    [No Abstract]   [Full Text] [Related]  

  • 33. [The estimation of treatment of Hymenoptera venoms allergy in children].
    Botulińska E; Piotrowska T; Korol D; Swiebocka E; Hofman J
    Pol Merkur Lekarski; 2006 Sep; 21(123):232-4. PubMed ID: 17163183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety considerations in assessing the role of immunotherapy in allergic disorders.
    Bousquet J; Michel FB
    Drug Saf; 1994 Jan; 10(1):5-17. PubMed ID: 8136087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects.
    Ceuppens JL; Bullens D; Kleinjans H; van der Werf J;
    Clin Exp Allergy; 2009 Dec; 39(12):1903-9. PubMed ID: 20085600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of birch pollen-specific immunotherapy on birch pollen-related hazelnut allergy.
    van Hoffen E; Peeters KA; van Neerven RJ; van der Tas CW; Zuidmeer L; van Ieperen-van Dijk AG; Bruijnzeel-Koomen CA; Knol EF; van Ree R; Knulst AC
    J Allergy Clin Immunol; 2011 Jan; 127(1):100-1, 101.e1-3. PubMed ID: 20933256
    [No Abstract]   [Full Text] [Related]  

  • 37. In vitro evaluation of blocking antibodies by RAST interference during pollen desensitization: role of the IgG fraction.
    Chien YK; Anfosso F; Vervloet D; Charpin J
    Biomed Pharmacother; 1982; 36(3):145-9. PubMed ID: 7150707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Update on current care guidelines: Allergen specific immunotherapy].
    Valovirta E; Korhonen K; Kuitunen M; Kukkonen-Harjula K; Lammintausta K; Pallasaho P; Ralli P; Savolainen J; Toskala E; Virtanen T
    Duodecim; 2012; 128(1):108-9. PubMed ID: 22312833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Specific immunotherapy: indications and contraindications].
    Reinhardt MC
    Rev Med Suisse Romande; 1994 Mar; 114(3):233-43. PubMed ID: 8171233
    [No Abstract]   [Full Text] [Related]  

  • 40. Improved patient adherence to subcutaneous allergen immunotherapy using a modified rush immunotherapy protocol.
    Teachout J; Vandegrift S; Schafer C; Uekert S; Gell K
    Ann Allergy Asthma Immunol; 2019 Mar; 122(3):347-349. PubMed ID: 30308317
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.